天津发展(00882)发布公告，于2025年12月24日，力生制药（002393）(公司间接非全资附属公司)与兴业 银行订立第12份兴业银行理财协议，以本金金额人民币8500万元(相当于约港币9340.66万元)认购另一项 结构性存款。 ...

Group 1 - The company Tianjin Development (00882) announced a financial agreement with Industrial Bank for a structured deposit [1] - The agreement involves a principal amount of RMB 85 million, equivalent to approximately HKD 93.41 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號：882） 須予披露交易 第十二份興業銀行理財協議 茲提述本公司日期二零二五年六月十一日、二零二五年六月十九日、二零二 五年九月十日及二零二五年十一月十九日之公告，內容有關前興業銀行理財 協議。 於二零二五年十二月二十四日，力生製藥（本公司間接非全資附屬公司）與 興業銀行訂立第十二份興業銀行理財協議，以本金金額人民幣 85,000,000 元 （相當於約港幣 93,406,593 元）認購另一項結構性存款。 上市規則涵義 新認購事項（按單獨基準計算）不構成本公司於上市規則第 14 章項下的須 予公布交易。 由於前認購事項及新認購事項均為本集團向同一銀行購入理財產品並仍然持 有的投資，故根據上市規則第 14.22 條，該等認購事項須作為一系列交易合 併計算。 由於根據上市規則第 14.07 條計算有關新認購事項的最高適用百分比率（與 前認購事項合併計算時）超過 5% ...

Core Viewpoint - Tianjin Development Holdings Limited has entered into three new main agreements with Tianjin Pharmaceutical Group Co., Ltd., aimed at renewing existing continuing connected transactions that will expire on December 31, 2025 [1] Group 1: Agreements Overview - The agreements include a sales main agreement, a processing entrustment agreement, and a pharmaceutical procurement agreement, collectively referred to as the 2025 Tianjin Pharmaceutical Main Agreements, effective from January 1, 2026, to December 31, 2026 [1] - The proposed annual caps for the agreements are set at RMB 90 million for sales transactions, RMB 70 million for processing entrustment transactions, and RMB 20 million for pharmaceutical procurement transactions [2] Group 2: Compliance and Monitoring - The company has implemented internal control measures, and the transactions will be regularly reviewed by external auditors and independent non-executive directors to ensure fair pricing and terms that are not more favorable than those offered to independent third parties [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號：882） 由於根據二零二五年天津醫藥主協議項下各自擬進行之交易的建議年度上限計 算之一項或多項適用百分比率（盈利比率除外）超過0.1%但低於5%，訂立上 述協議及其項下各自擬進行之交易須遵守上市規則第14A章之申報、公告及年 度審閱規定，但獲豁免遵守通函及獨立股東批准之規定。 緒言 茲提述本公司日期為二零二四年十一月十五日內容有關現有銷售主協議、現有委 託加工主協議及現有醫藥採購主協議的公告。 由於現有天津醫藥主協議將於二零二五年十二月三十一日屆滿，故於二零二五年 十二月二十二日，本公司與天津醫藥訂立二零二五年銷售主協議、二零二五年委 託加工主協議及二零二五年醫藥採購主協議，以重續現有天津醫藥主協議項下擬 進行之持續關連交易，自二零二六年一月一日起至二零二六年十二月三十一日止 為期一年。 - 1 - 重續與天津市醫藥集團有限公司的 現有持續關連交易 茲提述本公司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 天津發展控股有限公司 | | | 呈交日期: | 2025年12月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00882 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 1,072,770,125 | | 0 | | 1,072,770,125 | | 增加 / ...

Group 1 - The core viewpoint emphasizes the importance of technological innovation in driving industrial innovation and developing new productive forces in Tianjin [1][2] - Nankai University's research team has developed perovskite solar cells that address issues of short battery life and high costs, while also improving stability in high-temperature environments [1] - Tianjin University’s neuroengineering team has focused on non-invasive brain-computer interfaces, achieving significant technological breakthroughs over a decade [1] Group 2 - Galileo (Tianjin) Technology Co., Ltd. has developed a digital twin intelligent operation and maintenance platform that serves over 85% of national rail transit lines, enhancing safety and efficiency in train operations [2] - The Tianjin High Education Science and Technology Innovation Park has incubated over 3,900 enterprises, reflecting nearly double growth in national key laboratories and sustained high R&D investment intensity [2] - The development of new productive forces in Tianjin is aligned with the goal of improving the quality of life for citizens, showcasing a commitment to transforming technological breakthroughs into tangible benefits [2]

Core Viewpoint - Tianjin Development (00882.HK) announced the signing of the eleventh wealth management agreement with Xingyin Wealth Management and Industrial Bank, involving a principal amount of RMB 30 million for subscribing to another fixed-income investment product [1] Group 1 - The agreement was established on November 19, 2025, indicating a future investment strategy [1] - The investment amount of RMB 30 million is approximately USD 4.2 million, reflecting the company's commitment to diversifying its investment portfolio [1]

Core Viewpoint - Tianjin Development (00882) has announced an investment of RMB 30 million (approximately HKD 32.82 million) in a fixed-income investment product through its indirect non-wholly owned subsidiary, Lifescience Pharmaceutical, in collaboration with Industrial Bank and its wealth management division [1] Group 1 - The investment agreement is the eleventh of its kind between Lifescience Pharmaceutical and Industrial Bank [1] - The transaction is set to take place on November 19, 2025 [1]

Core Viewpoint - Tianjin Development (00882) announced a new investment agreement involving its indirect non-wholly owned subsidiary, Lifesun Pharmaceutical (002393), which will invest in a fixed-income product through a financial agreement with Xingyin Wealth Management and Industrial Bank [1] Group 1 - Lifesun Pharmaceutical has entered into its eleventh financial agreement with Industrial Bank, committing a principal amount of RMB 30 million, equivalent to approximately HKD 32.82 million [1]